Glioblastoma (glioblastoma multiforme and grade IV astrocytoma) Cancer
Conditions
Interventions
There are two substudies:
1. Using dynamic 13C-MRI and MRSI in up to 11 brain tumour patients and
2. Using dynamic deuterium metabolic MRI and MRSI imaging (DMI) in up to 11 brain tumour patients
Wher
Sponsors
Cambridge University Hospitals NHS Foundation Trust
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Over 18 years old 2. Able to and provide written informed consent to participate 3. If female, postmenopausal or if women of childbearing potential (WOCBP) using a suitable contraception 4. If male, using a suitable contraceptive method for the duration of the study
Exclusion criteria
Exclusion criteria: 1. Contraindication or inability to tolerate MRI 2. Pregnant or actively breast-feeding woman 3. If using an intrauterine contraceptive device (IUCD) as a method of contraception the device should be MRI safe at 3 T (researcher to confirm) 4. High blood glucose level (as determined by the researcher) that may have an impact on the study results 5. Significant medical or psychiatric history rendering the subject ineligible as deemed by the investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Using MRI imaging: 1. 13C. Spatial maps of area under the curve (AUC) timecourse sums of signals from hyperpolarized pyruvate, lactate, and any other metabolites detected, and ratios between these metabolite AUCs. Also estimates of the kinetic rate constants of conversion between injected tracer pyruvate and the metabolites formed (lactate, other). The timecourse typically covers approximately 1 minute beginning approximately 16 seconds after the start of injection. 2. DMI. Spectral peak intensity ratios between deuterated water, glucose, glutamate (brain only), lactate and lipids. These will be either in spatial maps derived from 3D spectroscopic imaging, or in unlocalized spectra from the whole sensitive volume of the coil. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Tumour response evaluations based on RECIST within ten weeks of starting radiotherapy 2. Tissue expression (archival or fresh tissue) of metabolic and other markers (such as LDH) measured using RT PCR at the time of standard-of-care surgery. | — |
Countries
England, United Kingdom
Contacts
Public ContactMarta Wylot
Outcome results
None listed